Atea Pharmaceuticals (AVIR) Assets Average: 2020-2022
Historic Assets Average for Atea Pharmaceuticals (AVIR) over the last 2 years, with Sep 2022 value amounting to $690.5 million.
- Atea Pharmaceuticals' Assets Average fell 19.48% to $690.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $690.5 million, marking a year-over-year decrease of 19.48%. This contributed to the annual value of $818.3 million for FY2021, which is N/A change from last year.
- According to the latest figures from Q3 2022, Atea Pharmaceuticals' Assets Average is $690.5 million, which was down 2.17% from $705.8 million recorded in Q2 2022.
- Atea Pharmaceuticals' Assets Average's 5-year high stood at $857.5 million during Q3 2021, with a 5-year trough of $486.9 million in Q4 2020.
- Its 3-year average for Assets Average is $750.3 million, with a median of $776.6 million in 2021.
- As far as peak fluctuations go, Atea Pharmaceuticals' Assets Average surged by 66.00% in 2021, and later decreased by 19.48% in 2022.
- Over the past 3 years, Atea Pharmaceuticals' Assets Average (Quarterly) stood at $486.9 million in 2020, then spiked by 66.00% to $808.2 million in 2021, then dropped by 19.48% to $690.5 million in 2022.
- Its Assets Average stands at $690.5 million for Q3 2022, versus $705.8 million for Q2 2022 and $745.0 million for Q1 2022.